Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III trial of ciclosporin for the prevention of reperfusion injury after myocardial infarction in China.

Next Previous
X
Search
Trial Profile

Phase III trial of ciclosporin for the prevention of reperfusion injury after myocardial infarction in China.

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 21 Sep 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ciclosporin (Primary)
  • Indications Myocardial infarction; Reperfusion injury
  • Focus Therapeutic Use

    • Most Recent Events

    • 26 May 2015 According to NeuroVive Pharmaceutical media release, data from this trial will be used to seek market approval for CicloMulsion in a number of Asian countries for the treatment of reperfusion injury following myocardial infarct.
    • 04 Jun 2013 New trial record
    • 29 May 2013 An application to conduct this trial is being prepared for the Chinese health care regulation agency, according to a NeuroVive media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top